Kymera Therapeutics Inc’s filing revealed that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.45 million on Dec 08 ’25. In the deal valued at $89.76 per share,5,000 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 0 shares worth roughly $0.0.
Then, Mainolfi Nello sold 100,000 shares, generating $8,917,000 in total proceeds. Upon selling the shares at $89.17, the Chief Executive Officer now owns 660,482 shares.
Before that, Gollob Jared sold 49,307 shares. Kymera Therapeutics Inc shares valued at $4,371,833 were divested by the Chief Medical Officer at a price of $88.67 per share. As a result of the transaction, Gollob Jared now holds 109,992 shares, worth roughly $10.37 million.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who remained covering the stock and in late October has reiterated a ‘”a Buy”‘ rating for it. Mizuho began covering KYMR with “an Outperform” recommendation on October 21, 2025. H.C. Wainwright maintained its rating on September 18, 2025. It rated KYMR as “a Buy”.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 41.55% to $94.3. Over the last five days, the stock has gained 41.04%. Kymera Therapeutics Inc shares have risen nearly 104.91% since the year began. Nevertheless, the stocks have risen 134.40% over the past one year. While a 52-week high of $68.80 was reached on 12/08/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 86.27, which if violated will result in even more drops to 78.25. On the upside, there is a resistance level at 102.66. A further resistance level may holdings at 111.03.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-11-14, growing by 0.46 million shares to a total of 8.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 8.12 million shares. There was a rise of 5.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 17, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
